Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
18.46
-0.25 (-1.34%)
At close: Mar 28, 2025, 4:00 PM
18.07
-0.39 (-2.11%)
After-hours: Mar 28, 2025, 5:16 PM EDT

Company Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.

The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.

Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics logo
Country United States
Founded 2022
IPO Date Jan 20, 2023
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Quang Pham

Contact Details

Address:
822 A1A North, Suite 306
Ponte Vedra, Florida 32082
United States
Phone 904 300 0701
Website cadrenal.com

Stock Details

Ticker Symbol CVKD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001937993
ISIN Number US1276361086
Employer ID 88-0860746
SIC Code 2834

Key Executives

Name Position
Quang X. Pham Chairman and Chief Executive Officer
Matthew K. Szot CPA, CPA Co-Founder and Chief Financial Officer
Jeffrey Cole Chief Operating Officer
Dr. James J. Ferguson FACC, M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 13, 2025 8-K Current Report
Mar 13, 2025 10-K Annual Report
Mar 4, 2025 8-K Current Report
Feb 12, 2025 SCHEDULE 13G/A Filing
Feb 7, 2025 8-K Current Report
Feb 3, 2025 S-8 Securities to be offered to employees in employee benefit plans
Jan 29, 2025 SCHEDULE 13D Filing
Jan 15, 2025 SCHEDULE 13G/A Filing
Dec 23, 2024 S-8 Securities to be offered to employees in employee benefit plans
Dec 20, 2024 424B5 Filing